TABLE 1.

Characteristics of articles included in the meta-analysis.

References	https://clinicaltrials.gov/ identifier	Phase	Duration	Age range, years	Reported treatment
Herring et al. (34)	NCT00792298	2	1 month	18–64	Suvorexant
Michelson et al. (36)	NCT01021813	3	1 year	≥18	Suvorexant
Herring et al. (23)*	NCT01097616 and NCT01097629	3	3 months	<65 and ≥65	Suvorexant
Fan et al. (32)	–	3	6 months	18–64	Suvorexant
Murphy et al. (37)	NCT01995838	2	6 months	19–80	Lemborexant
Rosenberg et al. (38)	NCT02783729	3	1 month	55–88	Lemborexant
Herring et al. (33)	NCT02750306	3	1 month	50–90	Suvorexant
Kärppä et al. (35)	NCT02952820	3	6 months	≥18	Lemborexant

*This article included four independent studies.